|
1
|
Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus.
|
Mol Ther
|
2004
|
1.21
|
|
2
|
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.
|
Mol Ther
|
2007
|
1.19
|
|
3
|
Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.
|
Hepatology
|
2005
|
1.17
|
|
4
|
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
|
Hum Gene Ther
|
2008
|
1.13
|
|
5
|
Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice.
|
Mol Ther
|
2003
|
1.09
|
|
6
|
Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism.
|
J Virol
|
2011
|
1.06
|
|
7
|
Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.
|
Mol Ther
|
2009
|
0.98
|
|
8
|
Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.
|
Hepatology
|
2008
|
0.98
|
|
9
|
Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
|
Laryngoscope
|
2007
|
0.96
|
|
10
|
Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
|
J Virol
|
2005
|
0.95
|
|
11
|
Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3.
|
Mol Ther
|
2008
|
0.94
|
|
12
|
Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence.
|
EMBO Mol Med
|
2013
|
0.92
|
|
13
|
Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas.
|
Otolaryngol Head Neck Surg
|
2007
|
0.92
|
|
14
|
Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus.
|
Int J Cancer
|
2005
|
0.90
|
|
15
|
Validation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolization.
|
J Hepatol
|
2011
|
0.89
|
|
16
|
Preoperative radiological characterization of hepatic angiomyolipoma using magnetic resonance imaging and contrast-enhanced ultrasonography: a case report.
|
J Med Case Rep
|
2011
|
0.85
|
|
17
|
Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma.
|
PLoS One
|
2010
|
0.82
|
|
18
|
Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.
|
Microb Biotechnol
|
2011
|
0.82
|
|
19
|
The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer.
|
Int J Mol Med
|
2012
|
0.79
|
|
20
|
Free-breathing quantitative dynamic contrast-enhanced magnetic resonance imaging in a rat liver tumor model using dynamic radial T(1) mapping.
|
Invest Radiol
|
2011
|
0.78
|
|
21
|
Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis.
|
Mol Ther
|
2013
|
0.78
|
|
22
|
Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMC.
|
Genet Vaccines Ther
|
2004
|
0.77
|
|
23
|
Posttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125.
|
J Virol
|
2012
|
0.77
|